Trial
NCT01856582
CD34+ Stem Cell Infusion to Augment Graft Function
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Children's Hospital Medical Center, Cincinnati
Collaborators
Hoxworth Blood Center
Condition
Waning Donor Chimerism
Intervention
CD34+
Why stopped
CliniMACS CD34 Reagent System was FDA approved for clinical use; therefore, patients were treated clinically.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-22